What Researchers Did
The authors reviewed the medical treatments used for active Crohn's disease and pointed toward possible new treatment options.
What They Found
This review of medical treatments for active Crohn's disease found that no definite breakthrough had occurred in recent years, and that results across treatments have varied. The newer salicylates showed some effect at higher doses but did not meet the expectations once connected with their development. The newer steroids compared well to, but did not exceed, older corticosteroids in effectiveness, with a better side-effect profile. Azathioprine and 6-mercaptopurine are slow to take effect and are steroid sparing, while methotrexate has limited controlled data and toxicity concerns. Cyclosporine use is controversial and linked to serious adverse events. Early studies of newer immune-modulating therapies were encouraging, but large-scale studies were still awaited.
What This Means for Canadian Patients
The abstract does not address hyperbaric oxygen therapy (HBOT). It covers only drug treatments for active Crohn's disease, such as salicylates, steroids, immune-suppressing drugs and immune-modulating therapies. Patients with Crohn's disease should talk with their gastroenterologist about these drug options.
Canadian Relevance
No direct Canadian connection identified.
Study Limitations
This is a narrative review from 1998, so it does not report new patient data, and its own conclusions say large-scale studies of the newer immune therapies were still needed to judge their effects and side effects.